Lipocine Inc.
- Open
- 2.24
- Day high
- 2.29
- Day low
- 2.23
- Prev close
- 2.29
- Volume
- 21K
- Mkt cap
- $18M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.8
- P/S
- 9.2
- Yield
- —
- Per share
- —
Lipocine Inc. (LPCN) is a Healthcare company listed on NASDAQ. The stock is down 29% over the past year.
Lipocine Inc. (LPCN) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
LPCN earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.51 | $-0.54 | -5.9% | $1M | +634.8% |
| Mar 9, 2026 | $-0.61 | $-0.34 | +44.3% | $1M | +887.4% |
| Nov 6, 2025 | $-0.56 | $-0.59 | -5.4% | $114574 | -51.9% |
| May 8, 2025 | $-0.35 | $-0.35 | +0.0% | $93864 | -73.3% |
| Mar 13, 2025 | $-0.40 | $0.33 | +182.5% | $3M | +33.6% |
| Nov 7, 2024 | $-0.48 | $-0.44 | +8.3% | — | — |
| Aug 8, 2024 | $-0.78 | $-0.56 | +28.2% | $89565 | -69.1% |
| May 9, 2024 | $-0.68 | $0.66 | +197.1% | $8M | — |
| Mar 7, 2024 | $-0.53 | $-0.42 | +20.8% | $216188 | — |
| Nov 8, 2023 | $-0.57 | $-1.27 | -122.8% | $-3M | -1116.9% |
| Aug 10, 2023 | $-0.64 | $-0.68 | -6.3% | — | — |
| May 11, 2023 | $-0.42 | $-0.68 | -61.9% | $54990 | -93.0% |
LPCN insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 30, 2026 | Patel Mahesh V.director, officer: Chief Executive Officer | Grant | 52,781 | $2.49 |
| Jun 4, 2026 | Jene Jill M.director | Grant | 1,764 | $2.19 |
| Jun 4, 2026 | Higuchi John W.director | Grant | 1,764 | $2.19 |
| Jun 4, 2026 | Ono Richard Danadirector | Grant | 1,764 | $2.19 |
| Apr 7, 2026 | Higuchi John W.director | Buy | 40,000 | $2.03 |
| Apr 6, 2026 | Higuchi John W.director | Buy | 123,000 | $2.05 |
| Apr 6, 2026 | Patel Mahesh V.director, officer: Chief Executive Officer | Buy | 25,000 | $2.03 |
| Apr 2, 2026 | Patel Mahesh V.director, officer: Chief Executive Officer | Buy | 25,000 | $2.02 |
| Jan 5, 2026 | Patel Mahesh V.director, officer: Chief Executive Officer | Grant | 25,000 | $8.00 |
| Dec 19, 2025 | Fogarty Kristaofficer: Principal Accounting Officer | Grant | 20,786 | $4.20 |
| Dec 19, 2025 | Patel Mahesh V.director, officer: Chief Executive Officer | Grant | 8,629 | $4.20 |
| Jun 5, 2025 | Fink Jeffrey Arvindirector | Grant | 1,764 | $3.20 |
| Jun 5, 2025 | Ono Richard Danadirector | Grant | 1,764 | $3.20 |
| Jun 5, 2025 | Jene Jill M.director | Grant | 1,764 | $3.20 |
| Jun 5, 2025 | Papapetropoulos Spyrosdirector | Grant | 1,764 | $3.20 |
Source: LPCN SEC Form 4 filings, latest Jun 30, 2026. For informational purposes only — not investment advice.
See the full LPCN insider & 13F page →Lipocine Inc. company profile
Overview
Lipocine Inc. (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company founded and headquartered in Salt Lake City, Utah. The company went public in October 2013 and specializes in developing oral delivery solutions for pharmaceutical products that treat neuroendocrine and metabolic disorders. Lipocine's core focus is on creating oral formulations of drugs that traditionally have poor bioavailability when taken by mouth, particularly hormone-based therapies. The company's lead product, TLANDO, is an oral testosterone replacement therapy that has received FDA approval, representing a significant milestone in the company's development trajectory.
Business
Lipocine operates in the specialized biopharmaceutical sector, focusing on developing oral drug delivery systems for hormones and other compounds that are typically difficult for the body to absorb when taken orally. This field addresses a significant medical need, as many hormone therapies traditionally require injections, patches, or gels, which can be inconvenient and lead to poor patient compliance. The company's primary business revolves around several key product candidates. TLANDO is their flagship FDA-approved oral testosterone replacement therapy for men with hypogonadism, a condition where the body doesn't produce enough testosterone. This represents the company's main revenue-generating product and addresses a market traditionally dominated by topical gels and injectable formulations. Beyond TLANDO, Lipocine has developed a robust pipeline of investigational drugs. LPCN 1144 is an oral prodrug of bioidentical testosterone being developed for non-cirrhotic non-alcoholic steatohepatitis (NASH), a serious liver condition. LPCN 1111 is another testosterone formulation designed for once-daily dosing in hypogonadal men. LPCN 1148 targets decompensated cirrhosis management, while LPCN 1154 is being investigated for postpartum depression treatment. The company also has programs targeting women's health, including LPCN 2101 for women with epilepsy and LPCN 1107, an oral hydroxyprogesterone caproate product for preventing recurrent preterm birth. These diverse applications demonstrate Lipocine's platform approach to oral drug delivery across multiple therapeutic areas. Revenue generation is currently concentrated in TLANDO sales, which likely represents the majority of the company's commercial revenue, though the company also generates some income from licensing arrangements and milestone payments from development programs.
Revenue model
Lipocine's business model centers on product sales of approved pharmaceuticals and potential future licensing arrangements. The company generates revenue primarily through commercial sales of TLANDO, their FDA-approved oral testosterone replacement therapy, which is sold to patients through traditional pharmaceutical distribution channels including pharmacies and healthcare providers. The company's customers are primarily men diagnosed with hypogonadism who require testosterone replacement therapy. Healthcare providers prescribe TLANDO as an alternative to traditional testosterone delivery methods like gels, patches, or injections. The oral delivery format addresses patient preferences for convenience and discretion, potentially commanding premium pricing compared to generic alternatives. Beyond direct product sales, Lipocine's business model includes potential licensing opportunities and partnership arrangements for their pipeline candidates. The company may generate revenue through upfront payments, milestone payments, and royalties from pharmaceutical partners who license their oral delivery technology or specific drug candidates for development and commercialization. Several factors could significantly impact Lipocine's margins and profitability. Positive factors include the convenience premium that oral formulations can command over traditional delivery methods, potential market expansion as oral alternatives gain acceptance, and the company's proprietary formulation technology that could create barriers to generic competition. The growing awareness of testosterone deficiency and expanding treatment guidelines could also drive market growth. However, margin pressures could arise from several sources. Generic competition in the testosterone replacement therapy market remains intense, with established products like topical gels available at lower costs. Regulatory challenges or safety concerns related to testosterone therapy could impact demand. Manufacturing costs for specialized oral formulations may be higher than traditional dosage forms, and the company's limited scale compared to larger pharmaceutical companies could affect negotiating power with distributors and payers. Additionally, the clinical-stage nature of most pipeline products means significant research and development expenses continue to pressure overall profitability.
Competitive moat
Lipocine's competitive moat appears moderate but faces significant challenges in the highly competitive pharmaceutical industry. The company's primary competitive advantage lies in its proprietary oral delivery technology platform, which enables the development of orally bioavailable formulations of drugs that traditionally require alternative delivery methods. This technology represents intellectual property that could provide some protection against direct competition. The FDA approval of TLANDO provides a regulatory moat, as generic competitors would need to conduct their own clinical trials and receive separate FDA approval to market competing oral testosterone products. This regulatory barrier creates a window of market exclusivity, though the duration and strength of this protection depends on patent life and the complexity of generic development. However, Lipocine's moat faces several vulnerabilities. The testosterone replacement therapy market is highly competitive, with established products from major pharmaceutical companies including topical gels, patches, and injectable formulations that have strong market positions and physician familiarity. Many of these competing products are available as generics, creating significant pricing pressure. The company's small size relative to major pharmaceutical competitors limits its marketing reach and negotiating power with healthcare providers and payers. Large pharmaceutical companies have substantially greater resources for marketing, sales force deployment, and market access initiatives, which could limit TLANDO's market penetration despite its oral delivery advantage. Potential disruption could come from several sources. Competing oral testosterone formulations under development by larger pharmaceutical companies could erode Lipocine's first-mover advantage. Generic versions of existing testosterone products continue to pressure pricing across the entire market. Additionally, evolving treatment guidelines or safety concerns related to testosterone therapy could impact the entire market category. The company's pipeline products face similar competitive dynamics, with most therapeutic areas having established treatments and significant competition from well-funded pharmaceutical companies. While the oral delivery platform provides differentiation, the clinical and regulatory risks associated with drug development, combined with limited financial resources compared to larger competitors, suggest that Lipocine's moat is relatively narrow and faces ongoing competitive pressure.
Risks & safety
Lipocine presents a mixed margin of safety profile typical of small biopharmaceutical companies, with strong liquidity but ongoing profitability challenges. • **Liquidity Position**: Strong cash position with $3.4 million in cash and short-term investments as of Q1 2025, supported by current ratio of 15.6x and quick ratio of 15.6x, indicating excellent short-term liquidity coverage. • **Debt Profile**: Minimal debt with debt-to-equity ratio of 0.0%, eliminating solvency risk from leverage and providing financial flexibility for operations and development activities. • **Cash Burn**: Negative operating cash flow of $2.0 million in Q1 2025 and $1.2 million for full year 2024, indicating ongoing cash consumption though at manageable levels given current cash position. • **Profitability Metrics**: Volatile earnings with net loss of $1.9 million in Q1 2025 following small profit of $8,352 for full year 2024, reflecting the lumpy nature of pharmaceutical revenues and ongoing R&D expenses. • **Valuation Considerations**: Trading at 0.89x book value and Graham Net-Net ratio of 3.44x, suggesting potential undervaluation relative to tangible assets, though P/E ratios are volatile due to inconsistent earnings. • **Revenue Concentration**: Heavy dependence on TLANDO sales creates revenue concentration risk, with quarterly revenues ranging from $0 to $3.5 million, indicating potential volatility in commercial performance. • **Development Stage Risks**: Multiple pipeline candidates in clinical trials represent both opportunity and risk, with significant capital requirements for advancement and uncertain regulatory outcomes.
Recent development
Based on the available financial data, Lipocine has experienced significant strategic developments over the past few years, primarily centered around the commercialization of TLANDO and advancement of their pipeline candidates. The company achieved a major milestone with FDA approval of TLANDO, transitioning from a purely clinical-stage company to one with commercial revenue generation capabilities. The financial performance shows the characteristic volatility of a small biopharmaceutical company launching its first commercial product. Revenue patterns demonstrate the challenges of pharmaceutical commercialization, with quarterly revenues ranging from zero to $3.5 million, indicating ongoing efforts to establish consistent market penetration for TLANDO. The company achieved a rare profitable year in 2024 with net income of $8,352, though this was preceded by significant losses in 2022 and 2023. The company has maintained a strong balance sheet throughout this transition period, preserving cash resources while managing the expensive process of drug development and commercialization. The substantial reduction in cash burn from $11.9 million in 2022 to $1.3 million in 2024 suggests improved operational efficiency and the beginning of revenue contribution from TLANDO sales. Lipocine appears to be focusing resources on advancing multiple pipeline candidates simultaneously, including LPCN 1144 for NASH treatment, LPCN 1111 for hypogonadism, and several other hormone-related therapies. This diversified approach reflects the company's strategy to leverage their oral delivery platform across multiple therapeutic applications rather than relying solely on TLANDO's commercial success. The company's development strategy emphasizes their proprietary oral delivery technology as a platform that can be applied to various poorly bioavailable drugs, particularly in the hormone therapy space. This approach allows them to address multiple market opportunities while leveraging their core technological competency, though it also requires significant capital allocation across multiple development programs.
LPCN company profile · for informational purposes only — not investment advice.
Track LPCN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free